Zika virus protection by a single low dose nucleoside modified mRNA vaccination
By N. Pardi, Michael J. Hogan, Rebecca S. Pelc, Hiromi Muramatsu, H. Andersen, C. DeMaso, Kimberly A. Dowd, Laura L. Sutherland, R. Scearce, R. Parks and 27 more. Nature, 2017
808 citations recorded by the source corpus.
Zika virus (ZIKV) has recently emerged as a pandemic associated with severe neuropathology in newborns and adults. There are no ZIKV-specific treatments or preventatives. Therefore, the development of a safe and effective vaccine is a high priority. Messenger RNA (mRNA) has emerged as a versatile and highly effective platform to deliver vaccine antigens and therapeutic proteins. Here we demonstrate that a single low-dose intradermal immunization with lipid-nanoparticle-encapsulated nucleoside-modified mRNA (mRNA–LNP) encoding the pre-membrane and envelope glycoproteins of a strain from the ZIKV outbreak in 2013 elicited potent and durable neutralizing antibody responses in mice and non-human primates. Immunization with 30 μg of nucleoside-modified ZIKV mRNA–LNP protected mice against ZIKV challenges at 2 weeks or 5 months after vaccination, and a single dose of 50 μg was sufficient to protect non-human primates against a challenge at 5 weeks after vaccination. These data demonstrate that nucleoside-modified mRNA–LNP elicits rapid and durable protective immunity and therefore represents a new and promising vaccine candidate for the global fight against ZIKV.
Subfields: Epidemiology, Infectious Diseases, Public Health, Environmental and Occupational Health
View Paper: https://www.semanticscholar.org/paper/89bde1e36d38d3c45c8d461bf791435ad1f02452
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
Citations in the corpus
- Modified mRNA vaccines protect against Zika virus infection (2017, neutral): “Consistent with our results, a recent study also reported the utility of LNP-encapsulated mRNA encoding the prM and E genes as a candidate vaccine for ZIKV infection (Pardi et al., 2017).”
- Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery. (2019, neutral): “These LNPs produced virus-neutralizing antibody after single or two low-dose vaccinations in mice, rabbit, or NHPs.(164,180) It is noteworthy that antigen expression is not the ultimate criteria for assessing the effectiveness of a vaccine, and T cell activation may better reflect whether an immune ”
- Lipid Nanoparticle Systems for Enabling Gene Therapies. (2017, background): “The subcutaneous, intramuscular, or intradermal administration of LNP systems containing mRNA coding for protein antigens associated with multiple infectious diseases are yielding impressive immune responses in preclinical models, often resulting in complete protection from disease in rodents and no”
- mRNA Vaccines in the COVID-19 Pandemic and Beyond. (2021, methodology): “Ionizable LNPs were originally designed to deliver siRNA to the liver but were repurposed to deliver mRNA starting in 2015 and were found to be extremely efficient carriers (70) and potent inducers of adaptive immunity (52).”